Home » Infinity Pharmaceuticals Announces Agreement With AstraZeneca
Infinity Pharmaceuticals Announces Agreement With AstraZeneca
Infinity Pharmaceuticals, Inc. announced that Infinity has regained from MedImmune, which is wholly owned by AstraZeneca PLC, all development and worldwide commercialization rights for Infinity’s Hedgehog cell-signaling pathway inhibitor program, including its lead candidate IPI-926.
BioSpace
Upcoming Events
-
25Apr
-
07May
-
14May
-
30May